Literature DB >> 18715819

Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

Stephen T Sonis1, Brynmor A Watkins, Gregory D Lyng, Mark A Lerman, Kenneth C Anderson.   

Abstract

Osteonecrosis of the jaw is associated with aminobisphosphonate use in patients treated with intravenous doses for the prevention of bony metastases. A more complete understanding of the natural history of bisphosphonate-related osteonecrosis of the jaws (BRONJ), factors associated with risk, and its pathobiology has been limited by the availability of human material and the absence of clinical predictability. We now describe an animal model, developed in female Sprague-Dawley rats, in which we replicate many of the clinical, radiographic, and histologic features described in humans. Animals treated with a sequence of zoledronic acid (ZA) and dexamethosone (DX) over a one to three week period developed BRONJ-like changes following extraction of mandibular or maxillary molars. Whereas the extraction sites of control animals underwent predictable healing with rapid epithelialization, animals treated with ZA/DX demonstrated clinical and histological evidence of ulceration overlying areas of necrotic bone. In contrast to images from control animals, radiographs from animals treated with ZA/DX demonstrated poor definition of the alveolar ridge with mixed radiodensity. Modest increases in the extent of the inflammatory infiltrate were seen fourteen days after extraction in ZA-only treated animals compared to control or ZA/DX-treated rats. However, by post-extraction day 28, no differences were observed. Tissue vascularity was most pronounced in ZA-only treated animals compared to ZA/DX or control specimens. Apoptosis of epithelial cells was not observed in any experimental groups, and no evidence of Actinomyces was observed as determined by Periodic Acid Schiff (PAS) staining. The administration of ZA/DX preceding dental extractions in rats therefore results in the development of bony and soft tissue changes that are similar to those noted humans who develop BRONJ, and may provide a useful model for study of its pathogenesis, as well as strategies for its prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715819     DOI: 10.1016/j.oraloncology.2008.04.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  65 in total

1.  Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.

Authors:  M R Allen; D J Kubek; D B Burr; S L Ruggiero; T-M G Chu
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

3.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

4.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors:  Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal:  J Bone Miner Metab       Date:  2010-03-24       Impact factor: 2.626

5.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

6.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

7.  Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial.

Authors:  Viviane N Pacheco; Renan Langie; Jules R D Benfica; Jéssica C Munaretto; Adriana Etges; Deise Ponzoni; Edela Puricelli
Journal:  Int J Exp Pathol       Date:  2018-11-20       Impact factor: 1.925

8.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Authors:  Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2016-05-04       Impact factor: 6.741

9.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

10.  Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.

Authors:  Yinghua Zhao; Lei Wang; Yi Liu; Kentaro Akiyama; Chider Chen; Ikiru Atsuta; Tao Zhou; Xiaohong Duan; Yan Jin; Songtao Shi
Journal:  Calcif Tissue Int       Date:  2012-10-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.